2. GPCR/G Protein Neuronal Signaling
  3. Dopamine Receptor
  4. 2407527-16-4

2407527-16-4

Enlicitide chloride Chemical Structure

2407527-16-4

Chemical Structure

  • Enlicitide chloride
  • Synonym(s): MK-0616 chloride
  • CAS No: 2407527-16-4
    Formula: C82H110ClFN14O15
    Molecular Weight: 1586.29
  • InChIKey: CLOLWQCFULXMAR-QQCDJELVSA-N
  • SMILES: FC1=CC=C2C(C(C[C@@](NC([C@](NC([C@H](NC([C@@H](N3)C)=O)CNC(CCCCC[N+](C)(C)C)=O)=O)([H])CC4=CC=CC5=C4)=O)([H])C(N6[C@@](C(N[C@@](C(N[C@H](C(N(CCC7)[C@@]78C)=O)CC(C=C9)=CC=C9OC)=O)([H])[C@H](O)C)=O)([H])[C@](OCC(NC5)=O)([H])CC6)=O)=CN2CCCCCCN(C(CCC3=O)=O)CC%10=CC=C(CCNC8=O)C=C%10)=C1.[Cl-]

Biological Activity: Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1][2][3].

Cat. No. Product Name Purity Description
HY-P4153 Enlicitide chloride 98.74% Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.

References

[1]. Ding FX, et al. Preparation of cyclic peptides as PCSK9 antagonist compounds: World Intellectual Property Organization, WO2019246349. 2019-12-26.
[2]. WHO Drug Information-World Health Organization (WHO).
[3]. Ahamad S, et al., Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. J Med Chem. 2022 Dec 8;65(23):15513-15539. [Content Brief]

Keywords:

Enlicitide chloride